A. Mann

Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo

F. Koch-Nolte, Y. Duan, T. Magnus, 2022, Frontiers in Immunology.

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors

F. Koch-Nolte, P. Bannas, J. Hambach, 2022, Frontiers in Immunology.